Advertisement
Canada markets closed
  • S&P/TSX

    21,788.48
    -60.11 (-0.28%)
     
  • S&P 500

    5,469.30
    +21.43 (+0.39%)
     
  • DOW

    39,112.16
    -299.05 (-0.76%)
     
  • CAD/USD

    0.7323
    -0.0001 (-0.01%)
     
  • CRUDE OIL

    81.20
    +0.37 (+0.46%)
     
  • Bitcoin CAD

    84,601.09
    +521.87 (+0.62%)
     
  • CMC Crypto 200

    1,284.14
    +35.02 (+2.80%)
     
  • GOLD FUTURES

    2,331.20
    +0.40 (+0.02%)
     
  • RUSSELL 2000

    2,022.35
    -8.47 (-0.42%)
     
  • 10-Yr Bond

    4.2380
    -0.0100 (-0.24%)
     
  • NASDAQ futures

    19,986.00
    +13.75 (+0.07%)
     
  • VOLATILITY

    12.84
    -0.49 (-3.68%)
     
  • FTSE

    8,247.79
    -33.76 (-0.41%)
     
  • NIKKEI 225

    39,726.39
    +553.24 (+1.41%)
     
  • CAD/EUR

    0.6834
    +0.0002 (+0.03%)
     

Altimmune to Participate at Two Upcoming Investor Conferences

Altimmune, Inc
Altimmune, Inc

GAITHERSBURG, Md., May 29, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences:

  • Jefferies Global Healthcare Conference (New York, NY)
    Wednesday, June 5, 2024
    Fireside Chat at 2:00 p.m. Eastern Time

  • Goldman Sachs Global Healthcare Conference (Miami Beach, FL)
    Wednesday, June 12, 2024
    Fireside Chat at 9:20 a.m. Eastern Time

The sessions will be webcast and can be accessed by visiting the Events section of the Altimmune website.

ADVERTISEMENT

About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter

Company Contact:
Richard Eisenstadt                                                        
Chief Financial Officer                                                 
Phone: 240-654-1450                                                        
ir@altimmune.com

Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com
Julia Weilman
Burns McClellan
Phone: 646-732-4443
jweilman@burnsmc.com

Media Contact:
Danielle Cantey
Inizio Evoke Comms
Phone: 619-826-4657
Danielle.cantey@inizioevoke.com